Skip to content

Corporate
- Pitch
- Mission
- CSR
- Team
Technology
- Publications
Pipeline
Clinical trials
Newsroom
Partnerships

Home
Corporate
- Pitch
- Mission
- CSR
- Team
Technology
- Publications
Pipeline
Clinical trials
Newsroom
Partnerships
Contact

C

1 min read

[Newsletter -4] NEWS/INFOS

Author Bertrand Fabien
Published 24 mai 2020

May 22, 2020.

>> Official news bulletin for XAV19/Bulletin officiel du XAV19 <<

Download our newsletter (english version)
Télécharger notre newsletter (version française)

Related Posts

XENOTHERA publishes the clinical efficacy of XAV-19, its anti-COVID antibody, in Frontiers in Immunology

June, 2024. During its participation in ASCO, XENOTHERA….

Reflections on #AACR2024: our key insights and contributions

April, 2024. The AACR Annual Meeting in San Diego was a pivotal...

XENOTHERA announces the start of the second dose cohort in the FIPO trial

March, 2024. FIPO is the first-in-human trial of XON7, the first anti-solid...

Corporate
Technology
Pipeline

Clinical trials
Newsroom
Partnerships

Contact
Legal notice

XENOTHERA

21 rue La Nouë de Fer, 44200 Nantes, France

contact@xenothera.com

Media : xenothera@izsogood.co